cas 60239-18-1, DOTA | Articles data

Articles about 60239-18-1Total 30 be found

Article title
Article abstract
Author
Journal number and time
Download

Cherenkov Radiation-Mediated In Situ Excitation of Discrete Luminescent Lanthanide Complexes
Lanthanide luminescence, while ideal for in vivo applications owing to sharp emission bands within the optical window, requires high-intensity, short-wavelength excitation of small organic “antenna” chromophores in the vicinity of the lanthanide complex to access excited f-orbital states through intersystem crossing. Herein, we explored Cherenkov radiation of the radioisotopes 18F and 89Zr as an in situ source of antenna excitation. The effective inter- and intramolecular excitation of the terbium(III) complexes of a macrocylic polyaminocarboxylate ligand (hydration number (q)=0, quantum yield (φ)=47 %) as well as its analogue functionalized to append an intramolecular Cherenkov excitation source (q=0.07, φ=63 %) was achieved. Using conventional small-animal fluorescence imaging equipment, we have determined a detection limit of 2.5 nmol of Tb(III) complex in presence of 10 μCi of 18F or 89Zr. Our system is the first demonstration of the optical imaging of discrete luminescent lanthanide complexes without external short-wave excitation.
Cosby, Alexia G.,Ahn, Shin Hye,Boros, Eszter
p. 15496 - 15499
(2018)
Read Online

Photoresponsive host-guest chemistry and relaxation time of fluorinated cyclodextrin and T1=T* 2 arylazopyrazole-functionalized DOTA metal complexes
Light-responsive modulation of the longitudinal (T1) and transversal T *2) relaxation times of a fluorinated cyclodextrin has been achieved by host-guest complexation with arylazopyrazole-modified metal complexes in aqueous solution. This supramolecular concept can potentially be applied to the development of contrast agents for19F magnetic resonance imaging (MRI).
Simke, Julian,B?ckermann, Till,Bergander, Klaus,Klabunde, Sina,Hansen, Michael Ryan,Ravoo, Bart Jan
supporting information
p. 2186 - 2191
(2021/03/24)

Method for preparing contrast agent
The invention provides a method for preparing a contrast agent. Specifically, the preparation method comprises the following steps: enabling a complex liquid composition containing a macrocyclic chelate and lanthanide elements to sequentially pass through Relite CNS cationic resin and Relite 3As anionic resin to obtain a high-purity liquid solution, and then adjusting the pH value of the solution;and freeze-drying or low-temperature spray-drying to obtain a contrast agent solid, and further weighing a certain amount of the solid to prepare a contrast agent preparation for medical contrast.
-
Paragraph 0005; 0058-0061

(2020/07/24)

METHOD FOR PREPARING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID
Disclosed is a method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) of formula (II), comprising the following steps: carrying out an alkylation reaction on cyclen in formula (I) and XCH2COOR in the presence of an acid-binding agent in water; adjusting a pH value to separate out a crude product of DOTA; and recrystallizing. The preparation method of the present invention is applicable to large-scale industrial production of DOTA, the whole process does not need to adopt an ion-exchange resin or low-temperature refrigeration mode for purification, and the purity and yield of the product are higher.
-
Paragraph 0079; 0080

(2020/12/01)

Including and Declaring Structural Fluctuations in the Study of Lanthanide(III) Coordination Chemistry in Solution
The physicochemical properties of lanthanide(III) ions are directly linked to the structure of the surrounding ligands. Rapid ligand exchange prohibits direct structure-property relationships from being formed for simple complexes in solution because the property measured will be an average over several structures. For kinetically inert lanthanide(III) complexes, the simpler speciation may alleviate the problem, yet the archetypical complexes formed by ligands derived from cyclen are known to have at least four different forms in solution - each with a variation in the crystal field that gives rise to significantly different properties. Slow interchange between forms has been engineered, so that a single complex geometry can be studied, but fast or intermediate interchange between forms is much more commonly observed. The rapid structural fluctuation can report on the changing chemical environment and can be disregarded if a specific property of a lanthanide(III) complex is exploited in an application. However, if we are to understand the chemistry of the lanthanide(III) ions in solution, we must include the structural fluctuation that takes place even in kinetically inert lanthanide(III) complexes in our studies. Here, we have scrutinized the processes that determine the speciation of lanthanide(III) complexes of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA)-like ligands, in particular the processes that enable exchange between forms that have different physicochemical properties, exemplified by the exchange between the diastereomeric capped square-antiprismatic (cSAP) and capped twisted-square-antiprismatic (cTSAP) forms of DOTA-like lanthanide(III) complexes. In the characterization of a kinetically inert f-element complex, understanding the structural fluctuation in the system is critical because a single observed property can arise from a weighted average, from all forms present, or from a single form with a dominating contribution. Further, the experimental condition will influence both the distribution of lanthanide(III) species in solution and the rates of the processes that change the coordination sphere of the lanthanide(III) ions. This is highlighted using data from a series of cyclen-derived ligands with different pendant arms and different denticity. The data were obtained in experiments that take place on different time scales to show that the rate of the process that results in a structural change must be considered against the time of the experiment. We conclude that the structural fluctuations must be taken into account and that they cannot be predicted from the ligand structure. Thus, an estimate of the exchange rates between forms, the relative concentrations of the specific forms, and the effect of the specific structure of each form of the complex must be included in the description of the solution properties of f-element chelates.
Nielsen, Lea Gundorff,S?rensen, Thomas Just
(2019/11/14)

General Approach to Direct Measurement of the Hydration State of Coordination Complexes in the Gas Phase: Variable Temperature Mass Spectrometry
The formation of ternary aqua complexes of metal-based diagnostics and therapeutics is closely correlated to their in vivo efficacy but approaches to quantify the presence of coordinated water ligands are limited. We introduce a general and high-throughput method for characterizing the hydration state of para- and diamagnetic coordination complexes in the gas phase based on variable-temperature ion trap tandem mass spectrometry. Ternary aqua complexes are directly observed in the mass spectrum and quantified as a function of ion trap temperature. We recover expected periodic trends for hydration across the lanthanides and distinguish complexes with several inner-sphere water ligands by inspection of temperature-dependent speciation curves. We derive gas-phase thermodynamic parameters for discernible inner- and second-sphere hydration events, and discuss their application to predict solution-phase behavior. The differences in temperature at which water binds in the inner and outer spheres arise primarily from entropic effects. The broad applicability of this method allows us to estimate the hydration states of Ga, Sc, and Zr complexes under active preclinical and clinical study with as-yet undetermined hydration number. Variable-temperature mass spectrometry emerges as a general tool to characterize and quantitate trends in inner-sphere hydration across the periodic table.
Racow, Emily E.,Kreinbihl, John J.,Cosby, Alexia G.,Yang, Yi,Pandey, Apurva,Boros, Eszter,Johnson, Christopher J.
supporting information
p. 14650 - 14660
(2019/10/11)

Preparation method for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
The invention relates to a preparation method for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Specifically, the method uses a recrystallization method to obtain a high-purity compound represented by a formula I shown in the description, and further, meglumine and Gd2O3 are complexed with the compound represented by the formula I to obtain the gadoteric acid meglumine. The method disclosed by the invention is simple to operate, has low costs, and is green, environmentally friendly and suitable for large-scale production.
-
Paragraph 0058-0061

(2018/11/03)

Compositions for protecting skin
The purpose of the present invention is to provide a skin outer layer composition which does not have or has very low skin irritation or toxicity, and has a high ability to remove formaldehyde and heavy metals compared to conventional material. The present invention provides the skin outer layer composition comprising, as active ingredients, one or more selected from trientine or trientine derivatives represented by chemical formula 1, cyclen or cyclen derivatives represented by chemical formula 2, and cyclam or cyclam derivatives represented by chemical formula 3. In the above formulas, R_1, R_2, R_3, R_4, R_5 and R_6 are each independently hydrogen, -R_7-COOH or salts thereof, and R_7 is a C_1-C_5 aliphatic group, a substituted or unsubstituted aromatic group, or a heterocyclic six-membered or five-membered ring.COPYRIGHT KIPO 2018
-
Paragraph 0142-0143; 0146

(2018/05/29)

CA - 4 macrocyclic polyamine derivative and its anti-tumor properties
The invention discloses macrocyclic polyamine derivatives (represented by formula I) of CA-4 as well as a pharmaceutically acceptable salt or configurational isomers of the macrocyclic polyamine derivatives. The compounds can be used for inhibiting a tumor from genesis or growth. Substituent groups R1 and R2, ring A, and a linking group L are defined in the description. The invention further discloses a preparation method of the compounds shown as formula I, a medicament composition, and application of the compounds in treating tumor diseases.
-
Paragraph 0096; 0098; 0099

(2017/10/07)

DOTA SYNTHESIS
The present invention provides methods for the preparation of compounds useful in vivo therapeutic and diagnostic applications. In particular, the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane-1,4, 7,10- tetraacetic acid (DOTA) and also methods for the preparation of metal chelates of DOTA.
-
Page/Page column 9; 10; 11

(2017/07/14)

Novel polyazamacrocyclic receptor decorated core-shell superparamagnetic microspheres for selective binding and magnetic enrichment of palladium: Synthesis, adsorptive behavior and coordination mechanism
The development of economical and green technologies for the effective recovery of palladium has attracted worldwide attention in recent years. Magnetic separation involving the use of functional magnetic nanoparticles (MNPs) with superparamagnetic characteristics holds great promise in this respect. This study presents a novel class of core-shell structured superparamagnetic microspheres decorated with polyazamacrocyclic receptors, which show a highly-selective binding to Pd(ii) in HNO3 media. The superparamagnetic microspheres possess a high saturation magnetization (53.8 emu g-1) and high adsorption capacity (qmax ≈ 105.3 μmol g-1), affording efficient enrichment and fast separation (within 13 seconds) of palladium under an applied magnetic field. Adsorptive behavior was fully investigated combined with the corresponding theoretical analysis by using kinetic equations and Langmuir/Freundlich isotherm models. Moreover, the coordination mechanism of the polyazamacrocyclic receptors to Pd(ii) was carefully examined based on high resolution X-ray photoelectron spectroscopy (XPS) and FT-IR spectrophotometry. A suggested mechanism involving the synergistic effect of the cyclic amines and carboxyl arms of the polyazamacrocyclic receptors was proposed to describe the coordination manner, while explaining the selectivity to Pd(ii) in HNO3 solutions. From a practical perspective, the Pd(ii)-enriched microspheres could be readily regenerated for cycle use. We conclude that this kind of polyazamacrocyclic receptor decorated superparamagnetic microsphere is of potential use for the effective recovery of Pd(ii) as well as other precious metals.
Wu, Fengcheng,Ye, Gang,Yi, Rong,Sun, Taoxiang,Xu, Chao,Chen, Jing
p. 9553 - 9564
(2016/07/06)

PROCESS FOR PURIFYING 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID
A process for purifying a compound of formula (1), comprising the following steps: a) adding an acid to an aqueous solution of the compound of formula 1, including salts thereof so as to obtain a pH ≤ 3 whereby a slurry is obtained; and b) filtering the slurry and at least one time washing the obtained precipitate with a liquid comprising water; and c) dissolving the precipitate obtained in step b) in water to obtain an aqueous solution; and d) filtering of the solution obtained in step c) over a nanofiltration membrane having a Molecular Weight Cut Off in the range from 150 to 500 and wherein optionally, between step c) and step d) the pH of the aqueous solution is adjusted to a pH value in the pH range as specified by the manufacturer of the nanofiltration membrane. A process for preparing a gadolinium complex of the purified compound of formula 1 is also disclosed. This gadolinium complex can be used for making a pharmaceutical composition as a contrast agent for magnetic resonance imaging.
-
Paragraph 0081; 0082; 0083; 0084

(2015/09/22)

PROCESS FOR PRODUCING 1, 4, 7, 10-TETRAAZACYCLODODECANE-1, 4, 7, 10-TETRAACETIC ACID AND COMPLEXES THEREOF
The present invention relates to a process for producing 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) including salts and hydrates thereof of general formula (I) from the respective cyclen. Said process further involves the use of cationic- and anionic exchange resins and solvent treatments to remove the organic and inorganic contaminants. Any cations present in the raw DOTA or other contaminants resulting from the reaction of cyclen are largely reduced in early stages of the process allowing to obtain good yields of DOTA in a purified grade and in an easier and reliable way. The present invention is thus useful for the production of DOTA, of macrocyclic compounds comprising metal ions complexes thereof and of compositions comprising said macrocyclic compounds that can be used as contrast agents for magnetic resonance imaging.
-
Page/Page column 28-29

(2014/08/07)

PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES
The present invention relates to an improved process for the purification of polyaminocarboxylates such as DOTA, DTPA, DO3A-butrol, BOPTA.
-
Paragraph 0018

(2014/11/11)

PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES
The present invention relates to an improved process for the purification of polyaminocarboxylates such as DOTA, DTPA, DO3A-butrol, BOPTA.
-
Page/Page column 4; 5

(2013/06/06)

Gd3+ cFLFLFK conjugate for MRI: A targeted contrast agent for FPR1 in inflammation
Formyl Peptide Receptors (FPRs) are vital in the host inflammatory response, playing an important regulatory role in multiple diseases. A Gd(iii) DOTA conjugate of cFLFLFK has been synthesised which targets and visualises FPR1 upon leukocytes in the inflammatory response via magnetic resonance imaging for the first time.
Stasiuk, Graeme J.,Smith, Helen,Wylezinska-Arridge, Marzena,Tremoleda, Jordi L.,Trigg, William,Luthra, Sajinder Kaur,Iveson, Veronique Morisson,Gavins, Felicity N. E.,Long, Nicholas J.
p. 564 - 566
(2013/02/23)

DOTA-tris(OPp ester) as a bifunctional prochelator for the preparation of DOTA-peptide conjugates
Peptides containing the chelator DOTA have gained importance for molecular imaging and therapy with radionuclides. However, all synthons described for the convergent solid phase synthesis of DOTA-peptide conjugates show windows of stability that are too narrow to allow a clean and convergent deprotection process. The synthesis of the new prochelator DOTA-tris(OPp ester) starting from cyclen is reported. Using this prochelator for the synthesis of several DOTA peptide conjugates revealed that its cleavage - in contrast to the cleavage of DOTA-tris(tBu ester) conjugates - does not require an extended deprotection time, and therefore results in clean and homogenous products.
Jamous, Mazen,Haberkorn, Uwe,Mier, Walter
p. 6810 - 6814
(2013/01/15)

Chelating agent derivatives and compositions comprising the same for use in imaging methods
Chelating agent derivatives and methods to produce and use them are disclosed. The chelating agent derivatives comprise one or more chelating moieties attached either directly or via a linker to a phospholipid moiety. The chelating agent derivatives of the present invention are suitable to be incorporated in a great number of copies into a lipophilic nanoparticle or microparticle. They are advantageously used in imaging methods such as e.g. MRI.
-
(2009/06/27)

Imaging of Enzyme Activity
This invention relates to biochemistry and magnetic resonance imaging.
-
(2008/06/13)

Preparation and animal biodistribution of 166Ho labeled DOTA for possible use in intravascular radiation therapy (IVRT)
Owing to its favorable decay characteristics (T1/2 = 27 h, Eβ(max) = 1.85 MeV, Eγ = 81 keV) and its availability with a specific activity of 3.74.4GBq/mg from a moderate flux reactor, 166Ho can be considered as a potential radionuclide for intravascular radiation therapy (IVRT) using liquid-filled balloons. In the present work, studies on the use of 166Ho labeled 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as a possible agent for IVRT for the prevention of restenosis has been initiated. 166Ho was obtained by irradiating natural Ho2O3 powder and DOTA was synthesized by a multistep procedure. The optimum protocol of radiolabeling of DOTA with 166Ho was achieved by varying different reaction parameters. The complex was found to retain its stability for 7 days at room temperature. Bioevaluation studies carried out in Wistar rats showed that >95% of the injected activity was excreted within 3 h p.i. with almost no retention in any major organ. Both radiochemical and biological studies showed that 166Ho labeled DOTA can be further explored as a potential agent for IVRT. Copyright
Das, Tapas,Chakraborty, Sudipta,Banerjeel, Sharmila,Samuel, Grace,Sarma,Venkatesh, Meera,Pillai
p. 197 - 209
(2007/10/03)

Imaging thrombus with glycoprotein llb/llla antagonists
This invention relates to a method of using a radiolabeled small molecule antagonist of the platelet IIb/IIIa receptor for the diagnosis of arterial and venous thrombi.
-
(2008/06/13)

Method of treating tumors
A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.
-
(2008/06/13)

Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
This invention relates to a method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Furthermore, radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of Aβ peptides.
-
(2008/06/13)

Synthesis and isolation of active esters of DOTA
-
Mier, W.,Haberkorn, U.,Eisenhut, M.
p. S814 - S816
(2007/10/03)

1,4,7,10-tetraazabicyclo[8.2.2]tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
The present invention relates to the novel compound, 1,4,7,10-tetraazabicyclo[8.2.2]tetradecan-2-one of formula (I), its preparation and the use thereof for the preparation of tetraazamacrocycles. STR1
-
(2008/06/13)

Method for preparing radionuclide-labeled chelating agent-ligand complexes
Radionuclide-labeled chelating agent-ligand complexes that are useful in medical diagnosis or therapy are prepared by reacting a radionuclide, such as 90 Y or 111 In, with a polyfunctional chelating agent to form a radionuclide chelate that is electrically neutral; purifying the chelate by anion exchange chromatography; and reacting the purified chelate with a targeting molecule, such as a monoclonal antibody, to form the complex.
-
(2008/06/13)

Polypeptide derivatives
A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one chelating group linked to an amino group of said peptide, the chelating group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.
-
(2008/06/13)

Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
A simple method for the synthesis of 1,4,7,10-tetraazacyclododecane N,N'N ,N' -tetraacetic acid and 1,4,8,11-tetraazacyclotetradecane N,N',N ,N' -tetraacetic acid involves cyanomethylating 1,4,7,10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane to form a tetranitrile and hydrolyzing the tetranitrile. These macrocyclic compounds are functionalized through one of the carboxylates and then conjugated to various biological molecules including monoclonal antibodies. The resulting conjugated molecules are labeled with radiometals for SPECT and PET imaging and for radiotherapy.
-
(2008/06/13)

Lead(II) and Bismuth(III) Complexes of the Polyazacycloalkane-N-acetic Acids nota, dota, and teta
Lead(II) and bismuth(III) complexes of nota, dota, and teta were synthesized and their kinetic properties were investigated to show that the dota conplexes are the most inert over the pH range 4-12 and 1-10 for lead and bismuth, respectively.
Kumar, Krishan,Magerstaedt, Michael,Gansow, Otto A.
p. 145 - 146
(2007/10/02)

Manganese (II) chelate manufacture
The process of this invention for preparing Mn(II) chelate comprises forming the Mn(II) chelate by mixing manganese(II) oxide (insoluble) with an aqueous suspension comprising a molar equivalent or molar excess of the insoluble protonated chelating compound at a temperature of from 20° to 50° C. When the reaction is carried out with a protonated chelating agent in the absence of base, a precipitate of the protonated Mn(II) chelate is formed. A low osmolarity Mn(II) chelate solution can be formed from the precipitates by dissolving them in an aqueous solution of base. When the initial chelate forming reaction is carried out in a solution containing a molar equivalent or excess of sodium hydroxide, a low osmolarity solution of the Mn(II) chelate is directly formed with most chelating agents. Preferred chelating compounds for this process include DPDP, DTPA, DCTA, EDTP, DOTA, DOXA, DO3A and EDTA. The Mn(II) chelate precipitates and low osmolarity solutions formed by the above processes are also aspects of this invention.
-
(2008/06/13)